Report of Foreign Issuer (6-k)
08 August 2015 - 4:01AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Continuous Disclosure
Commission File Number: 001-12033
Nymox Pharmaceutical Corporation
9900 Cavendish Blvd., St. Laurent, QC,
Canada, H4M 2V2
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F [ X ] Form 40-F [
]
Indicate by check mark if the registrant
is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): [ ]
Indicate by check mark if the registrant
is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate by check mark whether by furnishing
the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [ X
]
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______________
Nymox Pharmaceutical Corporation
On July 31, 2015 Nymox Pharmaceutical Corporation received
formal approvals for its change of domicile to the Bahamas was effective.
At the Special Shareholders Meeting of Nymox on April 23, 2015 there
was a 94% majority shareholder vote in favor of the Company's change of domicile to the Bahamas. Subsequent to the majority
vote in favor, on July 31, 2015 the Company was informed that it has received formal approval from Corporations Canada. The Company's
Management are located in Bahamas, the U.S. and Europe. The Company currently maintains offices in the Bahamas, the U.S. and Canada.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
NYMOX PHARMACEUTICAL CORPORATION |
|
(Registrant) |
|
|
|
By: /s/ Paul Averback |
|
Paul Averback |
|
President and Chief Executive Officer |
Date: August 7, 2015
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024